News and Events


VitamFero anounces the awarding of two key patents in the US

These property titles will protect and secure the development programs launched by VitamFero to prevent outbreaks of bovine cryptosporidiosis and neosporosis.


VitamFero wins the 2017 CommBeBiz Innovation award in the agrifood category

This award recognizes the innovation driven by VitamFero's Provicol project and will enable the compagny to accelerate its European visibility and dynamic commercial development 


VitamFero further strengthens its leadership team with the appointment of its new Research Director

VitamFero, a French veterinary biotechnology company specialized in creating and developing innovative prophylactic solutions, is announcing the arrival of Dr. Sophie Barreteau, PhD, as Research Director.


VitamFero and Bioproperties (Anglais)

VitamFero (FR) and Bioproperties (AU) announce the execution of an exclusive, worldwide license, codevelopment and distribution agreement aiming to complete the development of VitamFero’s proprietary animal toxoplasmosis vaccine in Bioproperties’ facilities in Sydney, Australia. Through close cooperation between the partners, VitamFero will transfer its veterinary live, attenuated vaccine technology to Bioproperties who will take charge of manufacturing and continue development up to drug...


CAPAGRO and Anjou Amorçage (Anglais)

After a financing round of 2.7 million euro acquired last September, VitamFero, a biotechnology company that develops innovative therapies for the prevention of infectious and parasitic diseases in the veterinary health sector, announces the closing of its third financing round to the tune of €4.3 million with an additional investment of €1.6 million made jointly by two newcomers (CAPAGRO and Anjou Amorçage) and by the management team and business angels who had already participated in...


VitamFero expands its R&D

VitamFero has taken mainly local academic research from technology transfer into industrial development. The firm, which develops novel anti-infective prophylaxis in veterinary health, once again secures the support of François-Rabelais University of Tours at the Faculty of Pharmaceutical Sciences Philippe Maupas in gaining a tripling the surface allowed for the premises it has occupied since its inception. As a result, there are now nearly 250 square meters of office and laboratory space...


VitamFero successfully secures its third round of financing

VitamFero, a company developing novel anti-infective (notably anti-parasitics) prophylactic applications in animal health, has just secured a new capital increase in the amount of €2.7 million with GO CAPITAL (through the Ouest Ventures II fund), Pradeyrol Développement and Business Angels affiliated with Val de France Angels, accompanied by the original shareholders (i.e. CapDecisif Management, G1J Ile-de-France and individual investors) who thus renewed their confidence in, and support...